CuDox-LTSLs

CuDox-LTSLs (copper-doxorubicin low temperature-sensitive liposomes) is a preclinical-stage, temperature-sensitive liposomal formulation containing a pH-sensitive complex of copper(II) and doxorubicin (CuDox) within its core. Developed by researchers at the University of California, Davis, this formulation is designed to enhance the stability of doxorubicin in systemic circulation and minimize cardiotoxicity and other systemic side effects associated with free anthracyclines. The liposomes are composed of DPPC, MPPC, and DSPE-PEG2k. When exposed to mild hyperthermia (approximately 42°C) triggered by local ultrasound-mediated hyperthermia, the liposomes rapidly release the CuDox complex. In the acidic microenvironment of the tumor or lysosomes, the copper-doxorubicin complex dissociates, liberating active, free doxorubicin to exert its cytotoxic effects.

Other names

CuDox-LTSLCuDox-TSLCuDox-TSLscopper-doxorubicin temperature-sensitive liposomesliposomal copper-doxorubicin